Jardiance and Pregabalin Interaction: What Women Need to Know

What Is the Actual Interaction Between Jardiance and Pregabalin?

These two drugs do not interfere with each other's metabolism. Empagliflozin is cleared primarily by UGT1A3, UGT1A8, UGT1A9, and UGT2B7 glucuronidation, not by cytochrome P450 enzymes, and pregabalin is excreted almost entirely unchanged in urine without hepatic CYP metabolism. That means the classic "drug A blocks drug B's metabolism" mechanism simply does not apply here.

The real risk is additive pharmacodynamic overlap across two separate pathways.

How Empagliflozin Affects Your Fluid Balance

Jardiance works by blocking SGLT2 receptors in the kidney proximal tubule, forcing roughly 60 to 90 grams of glucose out of the body per day in urine and pulling water with it. This osmotic diuresis reduces plasma volume. The FDA-approved empagliflozin prescribing information lists volume depletion, hypotension, and dizziness as known adverse effects. In the EMPA-REG OUTCOME trial, symptomatic hypotension occurred in 4.5% of empagliflozin-treated patients versus 3.7% on placebo.

How Pregabalin Contributes Its Own Dizziness

Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing excitatory neurotransmitter release. This is why it controls neuropathic pain and seizures, and it is also why it causes CNS depression. In the prescribing data reviewed by the FDA, dizziness occurred in up to 43% of pregabalin-treated patients and somnolence in up to 28% across neuropathic pain indications.

The Overlap: Why It Matters for Women

When you combine volume-related orthostatic dizziness from Jardiance with CNS-mediated sedation and balance disruption from pregabalin, the net clinical result is a meaningfully elevated fall risk. Falls in women with type 2 diabetes carry significant consequences: women over 50 lose bone density faster after menopause, and osteoporotic fracture risk is already elevated in women with type 2 diabetes independent of bone density scores. Pregabalin is also known to cause peripheral edema in up to 16% of users, which may mask the dehydration signs you would otherwise use to catch Jardiance-related volume loss.

Sex-Specific Physiology: Why Women Experience This Differently

Women metabolize and respond to both drugs differently than men do, though this area is under-studied.

Volume Depletion and the Female Cardiovascular Response

Women have a lower total blood volume per kilogram of lean mass than men and have greater reliance on heart rate than stroke volume to compensate for orthostatic stress. A systematic review in Hypertension found that women are more susceptible to orthostatic hypotension at equivalent degrees of volume depletion. If you are already on antihypertensives, as many women with type 2 diabetes are, the threshold for symptomatic dizziness when adding pregabalin becomes lower.

The Menstrual Cycle and Sodium Balance

During the luteal phase, progesterone acts as a mild aldosterone antagonist, increasing sodium and water loss. If you are still cycling and you take empagliflozin during your luteal phase, your baseline volume status may already be slightly contracted before pregabalin adds CNS dizziness. No trial has formally mapped this interaction across the menstrual cycle. This is an evidence gap, and the clinical guidance here is extrapolated from first principles rather than directly studied data.

PCOS, Insulin Resistance, and Why Both Drugs Appear Together

Polycystic ovary syndrome affects an estimated 8 to 13% of women of reproductive age and is a strong driver of type 2 diabetes onset, which is why you might be on Jardiance. PCOS also carries elevated rates of neuropathic pain conditions and chronic pain syndromes, making pregabalin a plausible co-prescription in this population. Women with PCOS and type 2 diabetes who are prescribed both drugs should have explicit counseling on fall prevention and hydration.

Perimenopause and the Added Complexity

Estrogen withdrawal during perimenopause changes thermoregulation, sleep architecture, and autonomic nervous system tone. Vasomotor symptoms can mimic or amplify the dizziness caused by volume depletion. A perimenopausal woman taking Jardiance for type 2 diabetes or early cardiovascular protection who is also prescribed pregabalin for hot-flush-associated sleep disruption (an off-label but clinically used application) faces compounded dizziness from three separate mechanisms: hormonal vasomotor instability, SGLT2-mediated volume loss, and pregabalin-related CNS depression. Dose titration should be slower and standing blood pressure checks more frequent in this group.

Who This Combination Is and Is Not Appropriate For

The framework below reflects clinical reasoning based on the pharmacology above and current prescribing information. No head-to-head trial has tested this exact combination stratified by life stage.

Women for Whom the Combination May Be Reasonable

• You have type 2 diabetes with confirmed peripheral diabetic neuropathy and your neuropathic pain is not controlled by first-line agents such as duloxetine or topical agents
• You are well-hydrated, not on loop diuretics, and your baseline blood pressure is in the normal range (systolic above 110 mmHg)
• You are post-menopausal and not experiencing active vasomotor symptoms that could amplify dizziness
• You have stable kidney function with eGFR above 45 mL/min/1.73m2 (the threshold below which empagliflozin loses glycemic efficacy per FDA labeling)
• Your prescriber has reviewed your fall history and home environment

Women for Whom Extra Caution or an Alternative Is Warranted

• You are actively trying to conceive, pregnant, or breastfeeding (see dedicated section below)
• You are perimenopausal with active vasomotor symptoms and disrupted sleep
• You take a loop diuretic, ACE inhibitor, or ARB alongside Jardiance, adding further hypotension risk
• You have a history of falls or balance disorders
• You have stage 3b or worse chronic kidney disease, because pregabalin accumulates significantly when eGFR drops below 60 mL/min and requires dose reduction per its FDA label
• You have a current or past substance use disorder, because pregabalin is a Schedule V controlled substance with documented abuse potential

Pregnancy, Lactation, and Contraception

This section is required for any article discussing these two drugs together. Both carry pregnancy-relevant warnings and their combination during pregnancy has not been studied in any formal trial.

Empagliflozin in Pregnancy

Empagliflozin is not approved for use during pregnancy. Animal reproduction studies showed kidney developmental toxicity in rats exposed during the equivalent of the second and third trimesters. The FDA prescribing label recommends discontinuing empagliflozin when pregnancy is detected and switching to insulin, which has the most safety data in pregnancy. Human data on in-utero empagliflozin exposure are limited to case reports and small pharmacovigilance series; no randomized or prospective cohort study has been completed. If you are of reproductive age and taking Jardiance, use reliable contraception and discuss the transition plan to insulin before attempting conception.

Empagliflozin passes into breast milk in animal studies. Human lactation transfer data are absent. Because SGLT2 inhibition in a nursing infant could theoretically disrupt kidney development, the FDA label advises against use while breastfeeding.

Pregabalin in Pregnancy

Pregabalin carries a more specific human signal. A population-based cohort study published in JAMA Internal Medicine found a 1.6-fold increased risk of major congenital malformations with first-trimester pregabalin exposure compared with unexposed pregnancies after adjusting for confounders, though the absolute risk remained small. The FDA prescribing information includes a pregnancy exposure registry (1-888-233-2334) and recommends that women of childbearing potential use effective contraception. Because pregabalin is a Schedule V substance, contraception counseling at every visit is standard clinical practice.

Pregabalin is present in human breast milk at low concentrations. A small study found infant exposure was approximately 7% of the maternal weight-adjusted dose, which is generally below the 10% threshold used as a rough cut-off for lactation concern, but the infant CNS depression risk from even low-level sedating drug exposure is not zero. Decisions about breastfeeding while on pregabalin should be made with a clinician who can weigh maternal need against infant risk.

Contraception Requirement Summary

If you are taking pregabalin for any indication and are of reproductive age, your prescriber should document contraception at every visit. If you are also on Jardiance and using hormonal contraception, be aware that the osmotic diuresis from empagliflozin does not reduce hormonal contraceptive efficacy; there is no pharmacokinetic interaction between empagliflozin and combined oral contraceptives that would reduce contraceptive protection.

Monitoring: What Your Clinician Should Check

Regular monitoring makes this combination safer. The following are evidence-based checkpoints drawn from both drugs' FDA labeling and standard diabetes management guidelines.

At Initiation and After Any Dose Change

• Standing blood pressure at 1 and 3 minutes after rising from supine. A drop of 20 mmHg systolic or 10 mmHg diastolic defines orthostatic hypotension and should prompt dose re-evaluation.
• Renal function panel: empagliflozin efficacy and pregabalin clearance both depend on eGFR. Check within 4 weeks of starting or dose-escalating either drug.
• Weight and fluid status: an unexpected weight loss of more than 2 kg over 2 weeks may signal excess volume depletion.

Ongoing Every 3 to 6 Months

• HbA1c and fasting glucose to confirm empagliflozin is still meeting glycemic targets
• Signs and symptoms of diabetic ketoacidosis: nausea, vomiting, abdominal pain, shortness of breath. The FDA issued a drug safety communication in 2015 about SGLT2 inhibitor-associated DKA, noting it can occur even at near-normal blood glucose levels, which makes it easy to miss
• Peripheral edema from pregabalin, which can confound fluid status assessment
• Fall history at every visit, particularly for women over 50

Red Flags That Require Same-Day Contact

Call your clinician or go to an emergency room if you experience: sudden severe dizziness that prevents standing, signs of DKA (fruity breath, vomiting, confusion), or a fall resulting in impact to a joint or the head.

Diabetic Neuropathy in Women: Why the Underlying Condition Matters

Pregabalin is most commonly prescribed alongside Jardiance because both drugs may be used in type 2 diabetes, and diabetic peripheral neuropathy affects roughly 50% of people with long-standing type 2 diabetes. Women with diabetic neuropathy have a different symptom profile than men: they report more burning pain and less numbness, and they are more likely to have autonomic neuropathy affecting heart rate variability and blood pressure regulation. Autonomic neuropathy is itself a risk factor for orthostatic hypotension, meaning a woman with diabetic autonomic neuropathy on Jardiance is already at elevated fall risk before pregabalin is added.

The American Diabetes Association Standards of Care 2024 list pregabalin, duloxetine, and gabapentin as first-line options for painful diabetic neuropathy, with no sex-stratified guidance on choosing between them. Duloxetine may be preferred in women with comorbid depression or anxiety because it addresses both, and it does not carry pregabalin's sedation or abuse-potential profile.

Alternatives Worth Discussing With Your Clinician

If the dizziness combination from Jardiance plus pregabalin is limiting your daily function, these are worth raising:

• Duloxetine 60 mg daily for neuropathic pain: similar efficacy to pregabalin for diabetic neuropathy in a Cochrane review without the orthostatic hypotension overlap; however, it can raise blood pressure slightly
• Topical capsaicin 8% patch: no systemic absorption, no interaction with empagliflozin, appropriate when neuropathy is focal
• Gabapentin carries a very similar pharmacodynamic profile to pregabalin and does not eliminate the dizziness risk, but it is not a controlled substance and may be preferable if abuse-potential is a concern

Switching from empagliflozin to a different glucose-lowering agent is rarely the right answer if you have established heart failure or CKD, because empagliflozin reduced cardiovascular death or hospitalization for heart failure by 25% in EMPA-REG OUTCOME and these cardiovascular benefits are well-established.

What the Evidence Gap Means for Your Care

No randomized controlled trial has studied the empagliflozin-pregabalin combination specifically. The interaction databases (Lexicomp, Micromedex, Drugs.com) flag this as a moderate interaction based on pharmacodynamic reasoning rather than prospective trial data. Women have been historically under-represented in diabetes drug trials: in EMPA-REG OUTCOME, only 28.5% of participants were women, meaning sex-specific safety signals could be missed. The guidance in this article applies the available pharmacology data to women's physiology through clinical reasoning; none of it comes from a female-specific efficacy or safety trial of this combination. Ask your prescriber explicitly whether the dose of pregabalin can start at 25 to 50 mg rather than 75 mg to reduce early dizziness while you and your care team assess tolerability.